The investment is expected to be about $9.75 million, and funding is led by biotech executive Stavros Vizirgianakis, the devicemaker said in an Aug. 24 news release.
Proceeds from the transaction are expected to help working capital and general corporate purchases. The closing is expected to take place over two phases: one in August and one in October.
After the first closing, Mr. Vizirgianakis will be non-executive chair of Xtant’s board.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
